Literature DB >> 28273303

Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer.

Kyle Freischlag1, Zhifei Sun2, Mohamed A Adam2, Jina Kim2, Manisha Palta3, Brian G Czito3, John Migaly2, Christopher R Mantyh2.   

Abstract

Importance: Failing to complete chemotherapy adversely affects survival in patients with colorectal cancer. However, the effect of incomplete delivery of neoadjuvant radiotherapy is unclear. Objective: To determine whether incomplete radiotherapy delivery is associated with worse clinical outcomes and survival. Design, Setting, and Participants: Data on 17 600 patients with stage II to III rectal adenocarcinoma from the 2006-2012 National Cancer Database who received neoadjuvant chemoradiotherapy followed by surgical resection were included. Multivariable regression methods were used to compare resection margin positivity, permanent colostomy rate, 30-day readmission, 90-day mortality, and overall survival between patients who received complete (45.0-50.4 Gy) and incomplete (<45.0 Gy) doses of radiation as preoperative therapy. Main Outcomes and Measures: The primary outcome measure was overall survival; short-term perioperative and oncologic outcomes encompassing margin positivity, permanent ostomy rate, postoperative readmission, and postoperative mortality were also assessed.
Results: Among 17 600 patients included, 10 862 were men, with an overall median age of 59 years (range, 51-68 years). Of these, 874 patients (5.0%) received incomplete doses of neoadjuvant radiation. The median radiation dose received among those who did not achieve complete dosing was 34.2 Gy (interquartile range, 19.8-40.0 Gy). Female sex (adjusted odds ratio [OR] 0.69; 95% CI, 0.59-0.81; P < .001) and receiving radiotherapy at a different hospital than the one where surgery was performed (OR, 0.72; 95% CI, 0.62-0.85; P < .001) were independent predictors of failing to achieve complete dosing; private insurance status was predictive of completing radiotherapy (OR, 1.60; 95% CI, 1.16-2.21; P = .004). At 5-year follow-up, overall survival was improved among patients who received a complete course of radiotherapy (3086 [estimated survival probability, 73.2%] vs 133 [63.0%]; P < .001). After adjustment for demographic, clinical, and tumor characteristics, patients receiving a complete vs incomplete radiation dose had a similar resection margin positivity (OR, 0.99; 95% CI, 0.72-1.35; P = .92), permanent colostomy rate (OR, 0.96; 95% CI, 0.70-1.32; P = .81), 30-day readmission rate (OR, 0.92; 95% CI, 0.67-1.27; P = .62), and 90-day mortality (OR, 0.72; 95% CI, 0.33-1.54; P = .41). However, a complete radiation dose had a significantly lower risk of long-term mortality (adjusted hazard ratio, 0.70; 95% CI, 0.59-0.84; P < .001). Conclusions and Relevance: Achieving a target radiation dose of 45.0 to 50.4 Gy is associated with a survival benefit in patients with locally advanced rectal cancer. Aligning all aspects of multimodal oncology care may increase the probability of completing neoadjuvant therapy.

Entities:  

Mesh:

Year:  2017        PMID: 28273303      PMCID: PMC5831429          DOI: 10.1001/jamasurg.2017.0010

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  30 in total

1.  Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.

Authors:  Joakim Folkesson; Helgi Birgisson; Lars Pahlman; Bjorn Cedermark; Bengt Glimelius; Ulf Gunnarsson
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Improved survival with preoperative radiotherapy in resectable rectal cancer.

Authors:  B Cedermark; M Dahlberg; B Glimelius; L Påhlman; L E Rutqvist; N Wilking
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

3.  Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Medical Research Council Rectal Cancer Working Party.

Authors: 
Journal:  Lancet       Date:  1996-12-14       Impact factor: 79.321

4.  Completion of therapy by Medicare patients with stage III colon cancer.

Authors:  Sharon A Dobie; Laura-Mae Baldwin; Jason A Dominitz; Barbara Matthews; Kevin Billingsley; William Barlow
Journal:  J Natl Cancer Inst       Date:  2006-05-03       Impact factor: 13.506

5.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

Review 6.  Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation.

Authors:  Nuran Senel Bese; Jolyon Hendry; Branislav Jeremic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-30       Impact factor: 7.038

7.  Insurance status, comorbidity level, and survival among colorectal cancer patients age 18 to 64 years in the National Cancer Data Base from 2003 to 2005.

Authors:  Anthony S Robbins; Alexandre L Pavluck; Stacey A Fedewa; Amy Y Chen; Elizabeth M Ward
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

Review 8.  Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer.

Authors:  Wim P Ceelen; Yves Van Nieuwenhove; Kjell Fierens
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

9.  Centralization of cancer surgery: implications for patient access to optimal care.

Authors:  Karyn B Stitzenberg; Elin R Sigurdson; Brian L Egleston; Russell B Starkey; Neal J Meropol
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  Cancer survival disparities by health insurance status.

Authors:  Xiaoling Niu; Lisa M Roche; Karen S Pawlish; Kevin A Henry
Journal:  Cancer Med       Date:  2013-05-08       Impact factor: 4.452

View more
  4 in total

1.  Impact of Fluoropyrimidine and Oxaliplatin-based Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.

Authors:  Yuka Okada; Tsuyoshi Ozawa; Tamuro Hayama; Kohei Ohno; Mitsuo Tsukamoto; Yoshihisa Fukushima; Ryu Shimada; Keijiro Nozawa; Keiji Matsuda; Yojiro Hashiguchi
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Neoadjuvant Carboplatin/Paclitaxel versus 5-Fluorouracil/Cisplatin in Combination with Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Comparative Study.

Authors:  Xing Gao; Ping-Chung Tsai; Kai-Hao Chuang; Chu-Pin Pai; Po-Kuei Hsu; Shau-Hsuan Li; Hung-I Lu; Joseph Jan-Baptist van Lanschot; Yin-Kai Chao
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

3.  Identification of genes inducing resistance to ionizing radiation in human rectal cancer cell lines: re-sensitization of radio-resistant rectal cancer cells through down regulating NDRG1.

Authors:  Soon-Chan Kim; Young-Kyoung Shin; Ye-Ah Kim; Sang-Geun Jang; Ja-Lok Ku
Journal:  BMC Cancer       Date:  2018-05-25       Impact factor: 4.430

4.  Age as a potential predictor of acute side effects during chemoradiotherapy in primary cervical cancer patients.

Authors:  Annica Holmqvist; Gabriel Lindahl; Rasmus Mikivier; Srinivas Uppungunduri
Journal:  BMC Cancer       Date:  2022-04-07       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.